Atmus Filtration Technologies (ATMU) Stock
Specialized maker of inhalation devices for pharmaceutical partners. Here's the price, business snapshot, and what's worth knowing about Atmus Filtration Technologies in October 2026.
Atmus Filtration Technologies Inc (ATMU) develops inhalation and nasal drug‑delivery systems alongside filtration and device engineering services for pharmaceutical partners. The company aims to commercialise integrated device‑and‑drug solutions that can improve therapy delivery for respiratory and nasal conditions, leveraging specialised know‑how in aerosol and filtration technology. Key investor considerations include revenue potential from licensing and partner programmes, the need for regulatory approvals for device‑drug combinations, and the practical challenges of scaling manufacturing. With a market capitalisation of about $3.67bn, Atmus sits in a specialised part of the healthcare‑equipment market where collaborations and intellectual property matter. Risks include regulatory setbacks, competition from larger device makers, and variable adoption by pharma customers. This summary is general, educational information and not personal investment advice; values can rise or fall and past performance is not a reliable indicator of future returns.
Atmus Filtration Technologies (ATMU) Stock Forecast
Analyst price target, next 12 months
$53.72
+20.4% vs today's $44.61
Price range over the last 12 months
Close to its 12-month low
Analysts covering Atmus Filtration Technologies have a consensus 12-month target of $53.72, above the current price of $44.61.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ATMUS stock with a target price of $53.72, indicating good growth potential.
Financial Health
ATMUS Filtration Technologies is performing well with solid revenue and cash flow generation.
Dividend
ATMUS Filtration Technologies' low dividend yield of 0.49% suggests limited returns for dividend-seeking investors. If you invested $1000 you would be paid $4.90 a year in dividends (based on the last 12 months).
Baskets Featuring ATMU
The North Ablaze: Investing In Wildfire Resilience
This carefully selected group of stocks offers exposure to companies tackling Canada's unprecedented wildfire crisis. Our professional analysts have identified businesses positioned to benefit from increased spending on wildfire suppression, air quality solutions, and carbon monitoring technologies.
Published: 21 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth via Partnerships
Atmus’s collaborations with pharmaceutical companies can scale revenue through licensed device‑drug pairings, though outcomes depend on regulatory success and commercial adoption.
Technology Edge
Proprietary inhalation and filtration technologies may differentiate offerings and attract deals, but R&D and regulatory risk mean results are uncertain.
Demand Drivers
Global respiratory disease trends and ageing populations support long‑term demand for delivery devices, although competition and reimbursement pressures remain considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
